The relationship of LPA single nucleotide polymorphisms (SNPs), apolipoprotein(a) isoforms, and lipoprotein(a) [Lp(a)] levels with major adverse cardiovascular events (MACE) in different ethnic groups is not well known.
L ipoprotein(a) [Lp(a)] is an independent, genetic, and likely causal risk factor for myocardial infarction, stroke, peripheral arterial disease, 1, 2 and calcific aortic valve stenosis. 3, 4 Circulating Lp(a) levels are largely genetically determined by a variety of differences in the LPA gene. Several levels of LPA gene regulation determine plasma Lp(a) levels, including biochemical influences on transcription factors, variations in LPA single nucleotide polymorphisms (SNPs), and the inter-and intra-individual heterogeneity in kringle IV type 2 (KIV 2 ) isoform repeats. Physiological, dietary, and environmental factors play a relatively minor role and can either lower or raise Lp(a) plasma levels. 5 Furthermore, it is well appreciated that significant ethnic differences exist in Lp(a) levels, with the highest levels present in black subjects and generally followed in decreasing order of lower levels in southern Asians, whites, Hispanics, and East Asians. 2, 6, 7 LPA SNPs rs3798220 and rs10455872 in whites and rs9457951 in blacks have been shown to be associated with increased plasma Lp(a) levels in separate studies. 8, 9 However, the independent association of LPA SNPs and apolipoprotein(a) isoforms with major adverse cardiovascular events (MACE) in populations as a whole and in different ethnic groups is not well established. The goals of this study were to evaluate these 3 major, well-defined LPA SNPs in their relationship to Lp(a) levels and apolipoprotein(a) isoforms in different ethnic groups and assess the relationship between LPA SNPs and incident cardiovascular disease (CVD) events. This gap in the clinical database of Lp(a) is relevant in view of novel agents that can reduce Lp(a) levels, such as antibodies directed to proprotein convertase subtilisin kexin type 9 to bind circulating proprotein convertase subtilisin kexin type 9 generating immune complexes and preventing physiological action 10, 11 and antisense oligonucleotides directed to apolipoprotein(a) messenger ribonucleic acid to reduce apolipoprotein(a) protein synthesis and thereby prevent assembly of Lp(a). 12 The Dallas Heart Study (DHS) provides a unique prospective database with median 9.5-year follow-up to assess the relationships among white, black, and Hispanic subjects to provide insights into the atherogenicity of Lp(a). We hypothesized that elevated circulating Lp(a) levels rather than ethnic LPA genetic differences would be the key determinant in predicting incident cardiovascular events.
METHODS Study Subjects
The characteristics of the DHS subjects were previously described in detail. 7 The DHS is a multiethnic, probability-based sample of the Dallas County population in which blacks were systematically oversampled so they represented ≈50% of the final sample size. In this study, 3419 blood samples were available with complete data of LPA SNPs, apolipoprotein(a) isoforms, Lp(a) levels, and accompanying ethnic, biomarker, and MACE data from 2001 to 2010 for subsequent analyses. The Institutional Review Board of the University of Texas Southwestern Medical Center approved the study, and all participants provided informed consent in accordance with institutional guidelines. The human subject protection program at University of California San Diego approved the measurement of oxidative biomarkers.
Determination of LPA SNPs
The LPA variants rs3798220, rs10455872, rs9457951, rs1801693, rs41272110, and G+1/inKIV-8A were genotyped using a TaqMan assay on a 7900HT Fast Real-Time PCR instrument (Applied Biosystems) at 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1.5 minutes.
Determination of Lp(a) Levels and Apolipoprotein (a) Isoforms
Measurement of Lp(a) levels was performed with a well-validated assay that is independent of apolipoprotein(a) isoform size and reported in nmol/L. 13 Apolipoprotein(a) isoforms were measured as the total number of KIV repeats as previously described. 13 The analyses were based on size of the major apolipoprotein(a) KIV isoform visualized on agarose gel electrophoresis. 7 In this study, the major apolipoprotein(a) isoform was associated with the smaller of the 2 alleles in 87% of subjects.
Clinical Perspective
What Is New?
• What Are the Clinical Implications?
• Elevated Lp(a) and oxidized phospholipids on apolipoprotein B-100 are predictors of MACE in a multiethnic cohort.
• The data suggest that much of Lp(a)-mediated MACE is driven by oxidized phospholipids on Lp(a).
• LPA single nucleotide polymorphisms and isoforms did not have clinical utility in this study. Further research is needed to assess whether they add additional clinical value in specific patient populations.
Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) were measured as previously described in detail by chemiluminescent ELISA using the murine monoclonal antibody E06, which binds to the phosphocholine headgroup of oxidized but not native phospholipids. [14] [15] [16] The OxPL-apoB values are expressed as relative lights units reflecting the amount of E06 bound to OxPL on apoB particles captured on microtiter well plates with antibody MB47. The OxPL-apoB measure primarily (≈85% to 90%) reflects the OxPL on Lp(a), in which OxPL are bound both covalently to apo(a) and in the lipid phase of apoB, with the remaining (0%-15%) OxPL being present on non-Lp(a) apoB particles. 17 It is important to note that the OxPL-apoB measure only represents those OxPL recognized by E06 (ie, E06 immunoreactivity) and does not represent non-E06 detectable OxPL present on apoB particles. 17 
Determination of MACE
The subjects were followed from January 2001 to December 31, 2010, for a median of 9.5 years of follow-up. Event adjudication beyond 2010 is not currently available for the DHS. MACE was defined as cardiac death, nonfatal myocardial infarction, stroke/transient ischemic attack, unstable angina requiring hospitalization, and arterial vascularization that included coronary artery bypass surgery, percutaneous coronary intervention, carotid endarterectomy, carotid stenting, and peripheral artery revascularization. Of the 3419 individuals, all had complete LPA SNP, apolipoprotein(a) isoform, and biomarker data. Additionally, all-cause death adjudicated until December 31, 2010; however, this end point was not included in the MACE analyses because the causes of noncardiac death were highly heterogeneous and would appropriately test the Lp(a) cardiovascular hypothesis. From this group of 3419 individuals, 2929 had the MACE end point adjudicated until the latest follow-up of December 31, 2010; therefore, the MACE analyses were performed on these subjects. No significant baseline differences were found in the individuals with or without adjudicated MACE events.
Statistical Analyses
Analyses were performed with SPSS 23.0 software package. Continuous variables were presented as means±standard deviations or medians and interquartile range and dichotomous variables as percentages. Differences in baseline attributes between subjects were analyzed with analysis of variance and χ 2 test. Correlations between variables were determined with the Spearman test. The base-2 logarithms (log 2 ) of Lp(a), size of the major apolipoprotein(a) isoform, OxPL-apoB, and triglycerides were used to account for skewness in the distributions. Thus, hazard ratios for these variables reflect the change in hazard for an increase of 1 log 2 (the equivalent of a doubling of the value) in the measure. Multivariable Cox regression analysis was used to estimate the associations between LPA SNPs, the size of the major apolipoprotein(a) isoform, Lp(a), and OxPL-apoB levels and time to MACE, with adjustment for sex, age in deciles, smoking status, presence or absence of hypertension and diabetes mellitus, body mass index and levels of low-density lipoprotein (LDL)-cholesterol per 25 mg/dL increase, high-density lipoprotein (HDL)-cholesterol per 10 mg/ dL increase, and log 2 triglycerides. If a patient had more than 1 MACE event, then only the first event was counted.
RESULTS
Baseline Characteristics of the Study Group by Ethnicity Table 1 displays the baseline characteristics of the entire group and by individual ethnic group. Blacks tended to be older and have a higher prevalence of hypertension, diabetes mellitus, and current smoking. Lp(a) and OxPL-apoB levels were highest in blacks, followed by whites and then Hispanics. A similar but inverse association was noted in the major apolipoprotein(a) isoform among ethnic groups. Blacks also had higher HDL-cholesterol and lower triglyceride levels compared with the other groups.
The prevalence of LPA SNPs is shown in Table 1 , and all were significantly different among ethnic groups except G+1/inKIV-8A. Rs3798220 was most prevalent in Hispanics, rs10455872 in whites, rs9457951 in blacks, rs1081693 in Hispanics, and rs41272110 in whites.
All patients had adjudicated total mortality data, but the 490 patients without an adjudicated MACE did not have differences in Lp(a) or OxPL-apoB than patients with adjudicated MACE (online-only Data Supplement Table I ). They tended to be younger, male, and smokers with more hypertension, diabetes mellitus, and triglycerides but lower body mass index, total cholesterol, and LDL-cholesterol.
Relationship of LPA SNPs to Lp(a), OxPL-apoB, and Apolipoprotein(a) Isoforms by Ethnicity Table 2 displays the relationship of LPA SNPs to Lp(a), apolipoprotein(a) isoforms, and OxPL-apoB.
For rs3798220, in blacks, Lp(a) and OxPL-apoB levels were not significantly different among wild-type alleles, heterozygotes, and homozygotes. In whites, significant differences were noted in Lp(a), apolipoprotein(a) isoforms, and OxPL-apoB (P<0.001 for all), with carriers of the C allele having highly elevated Lp(a) and OxPLapoB levels and corresponding smaller isoforms. In Hispanics, significant differences were noted in Lp(a), apolipoprotein(a) isoforms, and OxPL-apoB (P<0.001 for all). However, in contrast to whites, an inverse association was present, with carriers of the C allele having lower Lp(a), lower OxPL-apoB, and larger isoform sizes. For rs10455872, Lp(a), OxPL-apoB, and apolipoprotein(a), isoforms were significantly different among wild-type alleles and heterozygotes and homozygotes among blacks, whites, and Hispanics (P<0.001 in all 3 ethnic groups for each measure), with carriers of the G allele having highly elevated Lp(a) and OxPL-apoB levels and corresponding smaller isoforms.
For
rs9457951, Lp(a), OxPL-apoB, and apolipoprotein(a) isoforms were significantly different among wild-type alleles and heterozygotes and homozygotes among blacks and Hispanics but not whites, with carriers of the G allele having highly elevated Lp(a) and OxPL-apoB levels. Blacks did not have correspondingly smaller isoforms, but Hispanics did.
For rs1801693 and rs41272110, variable differences were noted in Lp(a), OxPL-apoB, and apolipoprotein(a) isoforms among ethnic groups, and for G+1/inKIV-8A, no differences were noted (Table 2) .
Correlations Between LPA SNPs, Lp(a), and OxPLapoB and Size of the Major Apolipoprotein(a) Isoform Table 3 displays the correlation between LPA SNPs and Lp(a), OxPL-apoB, and size of the major apolipoprotein(a) isoform. rs3798220 was inversely associated with size of the major apolipoprotein(a) isoform in whites, positively in Hispanics, and not correlated in blacks. rs10455872 was inversely associated with size of the major apolipoprotein(a) isoform in all 3 groups. rs9457951 was positively associated in blacks, inversely in Hispanics, and not correlated in whites. Lp(a) was highly correlated with OxPL-apoB in blacks (Spearman r=0.87, P<0.001), whites (r=0.70, P<0.001), and Hispanics (r=0.63, P<0.001). The size of the major apolipoprotein(a) isoform was generally inversely associated with Lp(a) and OxPL-apoB. Finally, the 3 LPA SNPs did not correlate with each other in blacks and whites, but rs3798220 was negatively associated with rs10455872 in Hispanics.
For rs1801693, modest positive and inverse correlations were noted with Lp(a), OxPL-apoB, rs3798220, and rs10455872 depending on the ethnic group (Table 3) . Values are given as mean (SD) or median (interquartile range). For rs1801693, rs41272110, and G+1/inKIV-8A 3379, 3333 and 3395 subjects were genotyped.
BMI indicates body mass index; HDL-C, high-density lipoprotein-cholesterol; HTN, hypertension; KIV, kringle IV; LDL-C, low-density lipoproteincholesterol; Lp(a), lipoprotein(a); OxPL-apoB, oxidized phospholipids on apolipoprotein B-100; and VLDL-C, very low-density lipoprotein-cholesterol. Table 4 shows the results of sequentially adjusted Cox regression analysis of Lp(a), OxPL-apoB, and the major apolipoprotein(a) isoform with MACE in the entire group. Linear trends were significant for Lp(a), OxPL-apoB, and apolipoprotein(a) isoforms across quartiles. In unadjusted analyses, the hazard ratio (HR) 95% confidence intervals quartiles 3 of the size of the major apolipoprotein(a) isoform had a lower HR compared with quartile 1. Adjustment for sex, hypertension, diabetes mellitus, smoking, age in deciles, body mass index, LDL per 25 mg/dL, HDL per 10 mg/dL, and log 2 triglycerides did not materially change the results for Lp(a), OxPL-apoB, or size of the major apolipoprotein(a) isoform size. Addition of the 6 LPA SNPs to the model attenuated the risk slightly, but significance was maintained for Lp(a), OxPL-apoB, and size of the major apolipoprotein(a) isoform. For Lp(a), adding the size of the major apolipoprotein(a) isoform attenuated the risk further, and finally adding OxPLapoB resulted in loss of significance. For OxPL-apoB and the size of the major apolipoprotein(a) isoform, similar findings were present with the addition of Lp(a) fully attenuating risk. Removing arterial revascularization (percutaneous coronary intervention, coronary artery bypass grafting, carotid and peripheral arterial revascularization) for the MACE end point did not materially change the results.
The Figure, A through C, displays the cumulative eventfree survival curves for Lp(a), OxPL-apoB, and size of the major apolipoprotein(a) isoform over the median 9.5 year follow-up after adjustment for sex, hypertension, diabetes mellitus, current smoking, body mass index, age in deciles, LDL-cholesterol per increase of 25 mg/dL, log 2 triglycerides, HDL-cholesterol per increase of 10 mg/ dL, and by carrier status of rs3798220, rs15455872 and rs9457951, rs1801693, rs412722110, and G+1/ inKIV-8A. Separation of MACE was evident across all 4 quartiles.
Relationship Between Lp(a), OxPL-apoB, and Size of the Major Apolipoprotein (a) Isoform and Time to MACE by Ethnicity
In blacks, adjustment for sex, hypertension, diabetes mellitus, smoking, age in deciles, body mass index, LDL per 25 mg/dL, HDL per 10 mg/dL, and log 2 triglycerides, Lp(a) was a positive predictor [HR 3.01 (1.27-7.11), P=0.012] and the size of the major Quartiles for Lp(a): Q1<19.6, Q2>19.6 -<49.9, Q3>49.9 -<110.5, Q4>110.5 nmol/L. Quartiles for major isoform size: Q1<19.5, Q2>19.5 -<24.0, Q3>24.0 -<28.0, Q4>28.0 Kringle IV repeats. Quartiles for OxPL-apoB: Q1<2564, Q2>2564 -<4025, Q3>4025 -<8734, Q4>8734 RLU.
BMI indicates body mass index; HDL-C, high-density lipoprotein-cholesterol; HTN, hypertension; LDL-C, low-density lipoprotein lipoprotein; log 2, base-2 logarithms; Lp(a), lipoprotein(a); MACE, major adverse cardiovascular events; OxPL-apoB, oxidized phospholipids on apolipoprotein B-100; and SNP, single nucleotide polymorphism.
apolipoprotein(a) isoform and inverse predictor [HR 0.49 (0.27-0.88), P=0.17] of time to MACE (Table 5) . In whites, the size of the major apolipoprotein(a) isoform was an inverse predictor [HR 0.49 (0.27-0.88), P=0.017], whereas strong trends were noted for Lp(a) and OxPL-apoB. In Hispanics, OxPL-apoB [HR 13.4 (1.89-94,3), P=0 .009] was a predictor of time to MACE, with Lp(a) a strong trend. The interaction tests between ethnicity and Lp(a), OxPL-apoB, and the size of the major apolipoprotein(a) isoform were negative (P>0.05 for all).
DISCUSSION
This study demonstrates that the prevalence and association of LPA SNPs with size of apolipoprotein(a) isoforms, Lp(a), and OxPL-apoB levels are highly variable and ethnicity-specific. Depending on their association with small or large isoforms, LPA SNPs may be associated with either higher or lower Lp(a) and OxPLapoB levels in different ethnic groups. It is important to note that, irrespective and independent of the SNP association, elevated plasma levels of Lp(a) was an independent predictor of MACE in the overall group. Smaller apolipoprotein(a) isoform sizes were predictive of incident MACE, but this relationship was abrogated by LPA SNPs or Lp(a)/OxPL-apoB levels. Finally, adding OxPL-apoB levels, which primarily reflects OxPL on Lp(a), 17, 18 to the multivariable analyses abrogated the risk, consistent with the notion that much of the CVD risk of Lp(a) is driven by its content of proinflammatory OxPL. 16, [19] [20] [21] [22] [23] [24] [25] [26] This study provides clarity about the role of the LPA gene and elevated Lp(a) levels in predicting CVD risk by demonstrating that elevated circulating Lp(a) levels is the key variable in predicting CVD risk irrespective of ethnicity. Most of the prior data on LPA and Lp(a) have been generated in subjects of European descent. Significant controversy surrounds whether elevated Lp(a) levels are similarly associated with CVD risk in blacks, who tend to have the highest average Lp(a) levels. 7, 27 Interestingly, they tend to have larger isoforms, which are associated with such levels, rather than small isoforms, as has been shown in subjects of European descent. 28, 29 Because the key LPA SNPs and apolipoprotein(a) isoform sizes were measured in this study, their relative contributions alone and in conjunction with Lp(a)-mediated risk were additionally determined.
Consistent with the role of Lp(a) and OxPL-apoB in predicting future MACE, it can be concluded that small isoforms are primarily important to CVD risk prediction in that they contribute to higher OxPL-apoB and Lp(a), likely due to a shorter synthesis time in the hepatocyte. 30 This finding was seen in whites and Hispanics and not blacks, which is consistent with the fact that isoform size explains <50% of circulating Lp(a) levels. These data further demonstrate that LPA SNPs are likely to be markers rather than mediators of elevated Lp(a) and OxPL-apoB, and their association with Lp(a)/ OxPL-apoB appears to be due to their random cosegregation with apolipoprotein(a) isoform sizes. Similarly, LPA SNPs appear to be tagging SNPs for isoform size but not necessarily small isoforms. For example, SNP rs3798220 was present in 42.4% of Hispanics subjects but only in 4.3% of whites, yet it was associated with large isoforms and lower Lp(a) levels in Hispanics but small isoforms and higher Lp(a) levels in whites. For clinical translatability and to address the clinical question on what is the optimal "Lp(a)" measure, these data suggest that circulating Lp(a) levels are the main Quartiles for Lp(a): Q1<19.6, Q2>19.6 -<49.9, Q3>49.9 -<110.5, Q4>110.5 nmol/L. Quartiles for major isoform size: Q1<19.5, Q2>19.5 -<24.0, Q3>24.0 -<28.0, Q4>28.0 Kringle IV repeats. Quartiles for OxPL-apoB: Q1<2564, Q2>2564 -<4025, Q3>4025 -<8734, Q4>8734 RLU.
BMI indicates body mass index; HDL-C, high-density lipoprotein-cholesterol; HTN, hypertension; LDL-C, low-density lipoprotein lipoprotein; log 2, base-2 logarithms; Lp(a), lipoprotein(a); MACE, major adverse cardiovascular events; OxPL-apoB, oxidized phospholipids on apolipoprotein B-100; SNP, single nucleotide polymorphism; and TG, triglyceride.
ORIGINAL RESEARCH ARTICLE
261 variable in quantitating CVD risk rather than LPA SNPs or apolipoprotein(a) isoform size. In earlier studies, OxPL-apoB was either a similar or better reflector of Lp(a)-mediated risk, which is consistent with the fact that the presence of OxPL on Lp(a) is variable and may reflect the flux of OxPL particles in different pathophysiological situations as well as the OxPL carrying capacity of Lp(a) and Lp(a) particle number. 22, 23, 25, 31 For example, it was previously shown in DHS that high Lp(a) concentrations, which are also associated with small apo(a) isoforms (ie, higher particle number), had the highest correlation with OxPL-apoB, irrespective of ethnic group status. 7 Although the issue of ethnicity and Lp(a) risk has been controversial because of inconsistent results in black individuals, this study adds to the growing data that ethnicity by itself is not the relevant variable but the Lp(a) level within the ethnicity. Elevated Lp(a) in black individuals, who have higher average Lp(a) but also differences in the distribution of kringle repeats than whites, is a risk factor, as suggested by both the Atherosclerosis Risk in Communities Study (ARIC) with 20-year follow-up 27 and the recent results from the Multi-Ethnic Study of Atherosclerosis (MESA). 32 The prevalence of LPA SNPs are also highly variable according to ethnic status. For example, data derived primarily from European populations show that rs3798220 is a relatively infrequent SNP, present in 2% to 4% of community subjects. 8, [33] [34] [35] [36] However, the frequency of this SNP is increased in subjects with elevated Lp(a) levels, and 24% of Europeans who are in the >95th percentile for elevated Lp(a) (ie, >139 mg/ dL) carry this SNP.
36 rs3798220 is also more prevalent in individuals with CVD, such as in individuals undergoing apheresis for elevated Lp(a) (>60 mg/dL) for recurrent CVD events having an allele frequency of 26.2%. 37 Additionally, this SNP is also associated with increasing levels of OxPL-apoB, which are associated with increased CVD risk. 38, 39 In European populations, this SNP is associated with small apolipoprotein(a) isoforms, usually <22 KIV repeats, and markedly elevated Lp(a) levels, particularly in homozygotes. It is interesting to note that this SNP is not present at all in blacks, 40 is present in <10% in Asian Indians, but is more prevalent (11.6%) in East Asians, such as Chinese in Hong Kong. 41, 42 LPA SNP rs10455872 is present in 7% to 15% of the general population in Europeans. 8, 43, 44 Its prevalence increases with increasing Lp(a) levels and is present in 47% of northern Europeans with Lp(a) levels >95th percentile. rs10455872 was prevalent in 37.2% of individuals undergoing apheresis with progressive coronary artery disease. 37 Less is known about this SNP in non-European populations, but it was not associated with CVD or small isoforms in Japan in a genomewide association study or other similar East Asian populations. 42 The prevalence of rs9457951 is primarily associated with black subjects, but it only explains ≈5% of the contribution to Lp(a) levels. 9 Limitations of this study include the fact that the Hispanic group was smallest in size and had few events; therefore, the role of the LPA gene, Lp(a), and OxPLapoB levels may be underpowered for the MACE end point.
In conclusion, the relationship of the LPA gene to MACE is best explained by elevated plasma Lp(a) or OxPL-apoB levels and not by LPA SNPs or size of apolipoprotein(a) isoforms. Studies with potent and specific Lp(a)-lowering drugs are underway to test the hypothesis that lowering Lp(a) will reduce CVD risk in subjects with elevated Lp(a). 12 
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